英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
23692查看　23692　在百度字典中的解释百度英翻中〔查看〕
23692查看　23692　在Google字典中的解释Google英翻中〔查看〕
23692查看　23692　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Shaping the Future of Oncology for Patients l Exelixis
    Exelixis is an oncology-focused biotech company innovating cancer treatments for life Find out how we're dedicated to giving more patients hope for the future
  • Cancer Clinical Trials and Pipeline l Exelixis
    Discover the oncology portfolio we've created through internal development and strategic external partnerships
  • Investors and News | Exelixis
    Investors news Shaping the future of oncology Exelixis is expanding its global innovation engine to evolve how cancer is treated and deliver for physicians, patients and partners
  • Our Medicines for Cancer Patients l Exelixis
    Learn about CABOMETYX® and our other approved cancer medicines -- success fueled by our team’s data-driven, science-first approach
  • Building a Legacy of Oncology Excellence l Exelixis
    Building a legacy of excellence in oncology innovation The Exelixis story began in 1994 when our prominent team of founding scientists set out to use model system genetics to systematize drug discovery
  • Advancing Science for Cancer Treatments l Exelixis
    Inside Exelixis Advancing science for hope We are driven by a singular focus to bring life-enhancing cancer treatments to patients Powered by drug discovery and development excellence, we are thinking bigger and broader than ever before to expand our product portfolio and propel oncology innovation forward
  • Exelixis Announces Preliminary Fiscal Year 2025 Financial Results . . .
    Exelixis is currently in the process of finalizing its financial results for the quarter and fiscal year ended January 2, 2026, and the preliminary financial results presented in this press release are based only upon preliminary information available to Exelixis as of January 11, 2026
  • Search Careers at Exelixis
    At Exelixis, we continually nurture a culture of authenticity and personal and professional growth, taking pride in our collective ability to lean into changes and challenges alike, by supporting leaders and employees at every level
  • Exelixis Announces Zanzalintinib in Combination with an Immune . . .
    Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib
  • Evolving How Cancer is Treated l Exelixis
    Learn how we’re innovating oncology drug development to expand our horizons for what is possible in cancer care





中文字典-英文字典  2005-2009